Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Advanced Triple Negative Breast Cancer with BRCA1/2 Promoter Methylation
NCT03205761Phase 2Completed
- Sponsor
- GEICAM
- Start
- Oct 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in breast cancer, sponsored by GEICAM. Primary endpoint: Overall Response Rate at 8 weeks. Started Oct 2017; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03205761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03205761.